US20040053372A1 - Synthetic peptides, antibodies directed against them, and the use thereof - Google Patents
Synthetic peptides, antibodies directed against them, and the use thereof Download PDFInfo
- Publication number
- US20040053372A1 US20040053372A1 US10/356,342 US35634203A US2004053372A1 US 20040053372 A1 US20040053372 A1 US 20040053372A1 US 35634203 A US35634203 A US 35634203A US 2004053372 A1 US2004053372 A1 US 2004053372A1
- Authority
- US
- United States
- Prior art keywords
- glu
- asp
- prothrombin
- gly
- arg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6429—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/974—Thrombin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
Definitions
- the invention relates to synthetic peptides, to the use of these peptides for immunizing an animal and for purifying specific antibodies against the said peptides, to antibodies against these peptides, and to the use of these antibodies.
- the human organism has two systems, which are in equilibrium, to protect itself both from blood loss and from thromboses: the coagulation system and the fibrinolytic system.
- the relationship between the two systems ensures that insoluble fibrin polymers are produced initially to stop bleeding and, during wound healing, are cleaved again by the lytic progress of fibrinolysis.
- Plasmin and thrombin are the key enzymes in both systems. Under physiological conditions, the dynamic equilibrium between the coagulation and the fibrinolysis system is under the control of the thrombolytic activity of plasmin and the thromboplastic activity of thrombin.
- Thrombin is a typical serine protease and is synthesized in the form of an inactive precursor, prothrombin.
- Activation of prothrombin is based on proteolysis by coagulation factor Xa, which represents a central position within the coagulation cascade.
- Factor Xa itself has a special function in that it can be activated both by the extrinsic and by the intrinsic coagulation pathway.
- Activated factor X (factor Xa) activates prothrombin by specific cleavage of the prothrombin molecule at the peptide bonds following the tetrapeptide Ile-Glu-Gly-Arg.
- This cleavage produces, on the one hand, thrombin and, on the other hand, in equimolar concentration the prothrombin fragment F 1+2 . Since one molecule of thrombin and one molecule of prothrombin fragment F 1+2 are produced from each prothrombin molecule, cleaved, determination of the prothrombin fragment F 1+2 in blood or plasma allows a direct conclusion about the coagulation potential, which depends on the thrombin concentration present in blood or plasma.
- the quantification of thrombin or the prothrombin fragments F 2 /F 1+2 using radioimmunoassays is known from the state of the art.
- the antisera required are produced by using the prothrombin fragments F 2 and F 1+2 , obtained from purified prothrombin molecules for immunizing animals.
- the specific antibodies are concentrated from the resulting crude antisera by purification by immuno-adsorption on immobilized prothrombin and the corresponding fragments.
- the object of the present invention was to provide antigens which result in the production of specific antibodies against the prothrombin fragments F 2 /F 1+2 and thus allow rapid and accurate determination of the content of these fragments in biological fluids.
- the invention relates to peptides which have amino acid sequences which partly correspond to the carboxyl-terminal end of the fragments F 2 /F 1+2 resulting from the FXa cleavage of thrombin, and which contain the amino acid sequence H-Gly-Asp-Glu-Glu-Gly-Val-Trp-Cys-Tyr-Val-Ala-Gly-Lys-Pro-Gly-Asp-Phe-Gly-Tyr-Cys-Asp-Leu-Asn-Tyr-Cys-Glu-Glu-Ala-VaL-Gln-Glu-Glu-Thr-Gly-Asp-Gly-Leu-Asp-Glu-Asp-Ser-Asp-Glu-Glu-Arg-Ala-Ile-Glu-Gly-Arg-OH, in whole or in part, but at least the four carboxyl-terminal amino acids.
- Suitable for the preparation of the peptides according to the invention are conventional methods, for example Merrifield solid-phase peptide synthesis (G. Barany and R. B. Merrifield: “Solid-Phase Peptide Synthesis” in E. Gross and J. Meienhofer: The Peptides, Analysis, Synthesis, Biology, Adademic Press, Inc. 1980) as well as customary synthetic strategies constructing the peptides in the form of soluble peptide segments.
- the peptide of the structure H-Cys(SH)-Leu-Asp-Glu-Asp-Ser-Asp-Glu-Glu-Arg-Ala-Ile-Glu-Gly-Arg was particularly preferably prepared on the solid phase.
- the Fmoc group has been used as temporary protective group, and the permanent protective groups used were the O-t-Bu protective group for Asp and Glu, t-Bu for Ser, the Mtr group for Arg and the tert.-butylmercapto group for Cys.
- the C-terminal amino acids were immobilized via p-alkoxybenzyl ester groups which were bonded to 1% crosslinked polystyrene.
- the peptides were constructed with repeated elimination of the temporary protective group and condensation of the next, protected amino acid using a condensing agent, preferably a carbodiimide.
- the peptides were cleaved off the resin by acidolysis with simultaneous deprotection of the side-chain groups.
- Any sulfhydryl groups to be deprotected are deprotected using tri-n-butylphosphine according to the state of the art.
- the peptides were purified by ion exchange chromatography, RP-HPLC and gel permeation chromatography. The composition of the peptides was confirmed as correct by amino acid analysis.
- the peptide prepared according to the invention has an amino acid sequence which corresponds completely or in part to the amino acid sequence of prothrombin and is synthesized by one of the conventional processes for peptide synthesis, for example Merrifield synthesis.
- the selection of the appropriate sequence entails, where possible, selection of the regions which, due to their location on the protein and/or the antigenicity of the exposed epitope, can be predicted to have a highly antigenic effect.
- the synthetic peptide then has antigenic activity, so that an immune response is triggered by immunization.
- Activated factor X cleaves the prothrombin molecule at the recognition sequence Ile-Glu-Gly-Arg. Hitherto This tetrapeptide has been detected only in human and bovine prothrombin. The rarity of this tetrapeptide predisposes it for use as a specific feature of the prothrombin molecule.
- Prothrombin is cleaved by activated factor X next to the arginine of the sequence Ile-Glu-Gly-Arg.
- factor Xa generates a new carboxyl terminus which contains in the terminal region the two amino acids GLu and Arg which have a very high antigenicity index.
- Peptides or polypeptides which contain the recognition sequence of the factor Xa cleavage site at the C terminus are particularly well suited for immunization.
- the fragment produced by the action of factor Xa on prothrombin and which has the factor Xa recognition sequence at the C terminus has a chain length of 273 amino acids.
- Suitable for immunization are both the entire polypeptide as well as part-sequences of this peptide which, however, still need to have the factor Xa recognition sequence at the C terminus.
- a particularly preferred embodiment provides for the use of a tetradecapeptide, for example having the sequence Leu-Asp-Glu-Asp-Ser-Asp-Glu-Glu-Arg-Ala-Ile-Glu-Gly-Arg-OH. The only important point in each case is that the carboxyltenunal sequence of the molecule is exposed and results in the immunization.
- Shorter peptides suffice in cases where it is not intended for the peptide to trigger an immune response but it is intended that the only function of this peptide is to be recognized by existing antibodies.
- An embodiment appropriate for this is based on an octapeptide of the sequence Glu-Glu-Arg-ALa-lle-Glu-Gly-Arg-OH.
- the peptide used for the immunization can be prepared both by customary means by chemical synthesis and by purification of a polypeptide made available by genetic manipulation.
- a conceivable example would be genetic engineering synthesis of the prothrombin fragment F 2 or F 1+2 in E. coli controlled by a strong promoter, or else the synthesis, by genetic manipulation, of a peptide extending beyond the factor Xa cleavage site or a peptide which is subsequently cleaved in vitro by factor Xa, which is likewise obtained by genetic engineering, which results in accessibility to the desired antigenic carboxyl terminus.
- peptides which are intended to be used for immunization or those intended to be employed as an immunoadsorbent, to be coupled to a carrier molecule.
- carrier molecules examples include bovine serum albumin, ovalbumin and polysaccharides.
- the peptide or polypeptide is bound to keyhole limpet hemocyanin.
- synthetic peptides according to the invention are used as immunoadsorbents, it is advisable to couple to materials suitable for preparing solid matrices.
- a preferred embodiment provides for the coupling of short peptides, for example the abovementioned octapeptide, to Sepharose which has been activated with cyanogen bromide.
- Immunization of suitable animals with carrier-bound peptides results reproducibly in the production of antibodies.
- a preferred animal species for immunization and obtaining antibodies in this context is the rabbit, because in this case there is a favorable relationship between the blood volume obtainable and the expense of breeding and care.
- the immunoglobulin fraction relevant for specific assays can be enriched by customary immunoadsorption methods from an antiserum of this type generated in an animal using synthetic peptides according to the invention.
- it is preferred in this case likewise to use as material for a matrix of this type, which is employed for immunoadsorption, a peptide which is coupled to a carrier and has the same antigenic determinant as the peptide employed for the immunization.
- the peptide used for the purification by immunoadsorption can moreover be considerably shorter; the only prerequisite for use in purification of the desired antibody by immunoadsorption is that the antigenic determinant formed by this shorter polypeptide is recognized and efficiently bound by the desired antibody.
- the peptide used for purification of the antibodies by immunoadsorption can be, for example, an octapeptide, preferably the peptide H-Glu-Glu-Arg-Ala-Ile-Glu-GLy-Arg.
- antibodies are induced in the animal system by immunization with synthetic peptides and are purified by immunoadsorption. These antibodies react specifically with the peptides used for the immunization and purification. Depending on the sequence of the peptide used, these antibodies bind either only to the fragments F 2 and F 1+2 or else, if a peptide sequence which is exposed in the natural prothrombin molecule is chosen, to the intact prothrombin molecule.
- the antibodies obtained according to the invention can be employed for a number of immunoassays with a variety of designs.
- they are expediently coupled to a solid carrier, but are preferably immobilized by adsorption onto polystyrene tubes.
- the tubes prepared for the following immunoassays can then be stored, closed airtight, at 4° C.
- the amount of prothrombin fragments F 2 /F 1+2 is determined according to the invention by preincubation of the sample with immobilized antibodies of this type, with the concentration of the fragments F 2 /F 1+2 which are bound by the immobilized antibodies being detected by subsequent incubation with a second antibody.
- This second antibody must have a property which is measurable, for example the ability to react with or bind a chromogenic substrate.
- this second antibody is expedient for this second antibody to be coupled to a marker enzyme, preferably peroxidase.
- a marker enzyme preferably peroxidase.
- the prothrombin fragments F 2 /F 1+2 can also be determined by simultaneous incubation of the sample, preferably of plasma, and labeled antibodies with the immobilized antibodies. Also possible is a competitive determination method entailing competition of labeled and unlabeled prothrombin fragments F 2 /F 1+2 for the binding site on the immobilized antibodies.
- the concentration of prothrombin fragments F 2 /F 1+2 determined in this way provides information on the degree of activation of the prothrombin.
- the peptide was synthesized using a semiautomatic peptide synthesizer.
- 1 g of Fmoc-Arg (Mtr)-p-alkoxybenzyl ester-resin was deprotected with 15 ml of 20% piperidine/DMF (v/v) and then washed several times with DMF and isopropanol.
- 1 mmol of Fmoc-Gly (3-fold excess) and 203 mg of HOBt dissolved in 15 ml of DMF were added.
- 1.1 ml of a 1 M diisopropylcarbodiimide solution (dichloromethane) were added and then the coupling was carried out for 1.5 hours.
- Example 4 The antibodies obtained in Example 4 were diluted with tris buffer solution (0.025 mol/l, pH 7.6) to a concentration of 5 ⁇ g/ml and immobilized by adsorption onto polystyrene tubes. 250 ⁇ l of antibody solution were incubated in each tube at 20° C. for 20 hours, and then the liquid was removed by aspiration, and the tubes were sealed airtight and stored at 4° C.
- the samples to be assayed were diluted 1:1 with incubation buffer (0.01 mol/l tris, 0.01 mol/L EDTA, heparin (2 U/mL), 0.05% Tween, pH 7.6), and 200 ⁇ l samples in each tube (see Example 5a) were incubated at 37° C. for 30 min. The incubation solution was then removed, and the tube was washed twice with 500 ⁇ l of washing solution each time (0.02 mol/l sodium phosphate, 0.05% Tween, pH 7.6). Then 200 ⁇ l of peroxidase-conjugated anti-prothrombin antibodies were added, and the tubes were incubated at 37° C. for 30 min.
- substrate/chromogen solution hydrogen peroxide; o-phenylenediamine
- Plasma anticoagulated with citrate solution was recalcified with calcium chloride solution (final concentration of calcium chloride: 0.025 mol/l). Aliquots were removed at various times, and the reaction was stopped by addition of EDTA (0.1 mol/l), antithrombin III (3 IU/mL) and heparin (5 IU/ml). The samples were diluted 1:1 with incubation buffer and assayed using the ELISA.
- the peptides according to the invention which have an amino acid sequence which corresponds, in whole or in part, to the amino acid sequence of prothrombin and is antigenic thus induce binding-specific antibodies against each of the antigenic determinants present in the peptide. These specific antibodies can then be purified by immunoadsorption on peptides having the same antigenic determinants.
- the use of synthetic peptides has the considerable advantage that absolutely pure antigens are employed for the immunization, so that no cross-reaction whatever with other proteins or other parts of the prothrombin molecule can occur in the resulting immune serum.
- Preferably used according to the invention is a peptide which contains the factor Xa cleavage site.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention relates to synthetic peptides which have amino acid sequences which correspond, in whole or in part, to the amino acid sequence of prothrombin and are antigenic, to the use thereof for the immunization of an animal and for the purification of specific antibodies, to antibodies against these peptides, and to the use of the antibodies for the determination of the fragments F2/F1+2. The antibodies hitherto used for the determination of the content of the fragments F2/F1+2 have been induced by immunization with natural, highly purified prothrombin fragments F2/F1+2. The isolation of these prothrombin fragments is elaborate and costly, and the antibodies generated therewith show cross-reactions with intact prothrombin. Used for the immunization according to the invention are synthetic peptides which have amino acid sequences which correspond, in whole or in part, to the amino acid sequence of prothrombin and are antigenic. The resulting antibodies react specifically with the antigen used for the immunization; if the peptides contain the carboxyl-terminal amino acid sequence of the fragments F2/F1+2 resulting after cleavage of the prothrombin molecule with factor Xa, then the antibodies generated react specifically with the fragments F2/F1+2 but not with intact natural prothrombin, so that information can be gained about the degree of activation of prothrombin.
Description
- The invention relates to synthetic peptides, to the use of these peptides for immunizing an animal and for purifying specific antibodies against the said peptides, to antibodies against these peptides, and to the use of these antibodies.
- The human organism has two systems, which are in equilibrium, to protect itself both from blood loss and from thromboses: the coagulation system and the fibrinolytic system. The relationship between the two systems ensures that insoluble fibrin polymers are produced initially to stop bleeding and, during wound healing, are cleaved again by the lytic progress of fibrinolysis.
- Plasmin and thrombin are the key enzymes in both systems. Under physiological conditions, the dynamic equilibrium between the coagulation and the fibrinolysis system is under the control of the thrombolytic activity of plasmin and the thromboplastic activity of thrombin.
- Thrombin is a typical serine protease and is synthesized in the form of an inactive precursor, prothrombin. Activation of prothrombin is based on proteolysis by coagulation factor Xa, which represents a central position within the coagulation cascade. Factor X itself has a special function in that it can be activated both by the extrinsic and by the intrinsic coagulation pathway. Activated factor X (factor Xa) activates prothrombin by specific cleavage of the prothrombin molecule at the peptide bonds following the tetrapeptide Ile-Glu-Gly-Arg. This cleavage produces, on the one hand, thrombin and, on the other hand, in equimolar concentration the prothrombin fragment F1+2. Since one molecule of thrombin and one molecule of prothrombin fragment F1+2 are produced from each prothrombin molecule, cleaved, determination of the prothrombin fragment F1+2 in blood or plasma allows a direct conclusion about the coagulation potential, which depends on the thrombin concentration present in blood or plasma.
- The quantification of thrombin or the prothrombin fragments F2/F1+2 using radioimmunoassays is known from the state of the art. The antisera required are produced by using the prothrombin fragments F2 and F1+2, obtained from purified prothrombin molecules for immunizing animals. The specific antibodies are concentrated from the resulting crude antisera by purification by immuno-adsorption on immobilized prothrombin and the corresponding fragments. These antibody preparations are suitable for the determination of the prothrombin fragments F2/F1+2, but do not enable a complete differentiation between intact uncleaved prothrombin and the prothrombin fragments F2/F1+2 liberated by cleavage. Furthermore, the relatively low specificity of this antibody preparation permits determination of the antigen only by use of radioimmunoassays (RIA) which can be carried out in practice only if the conditions set out in the radiation protection regulations are observed and, for this reason, require relatively great technical elaboration and financial cost. Finally, it is continually necessary to prepare fresh antibodies labeled with radioactive isotopes because the isotope iodine-125 normally used for the radiolabeling of proteins has a half-life of only about 2 months.
- Hence the object of the present invention was to provide antigens which result in the production of specific antibodies against the prothrombin fragments F2/F1+2 and thus allow rapid and accurate determination of the content of these fragments in biological fluids.
- This object is achieved according to the invention by synthetic peptides which have amino acid sequences which partly correspond to the amino acid sequence of prothrombin and are antigenic.
- Thus the invention relates to peptides which have amino acid sequences which partly correspond to the carboxyl-terminal end of the fragments F2/F1+2 resulting from the FXa cleavage of thrombin, and which contain the amino acid sequence H-Gly-Asp-Glu-Glu-Gly-Val-Trp-Cys-Tyr-Val-Ala-Gly-Lys-Pro-Gly-Asp-Phe-Gly-Tyr-Cys-Asp-Leu-Asn-Tyr-Cys-Glu-Glu-Ala-VaL-Gln-Glu-Glu-Thr-Gly-Asp-Gly-Leu-Asp-Glu-Asp-Ser-Asp-Glu-Glu-Arg-Ala-Ile-Glu-Gly-Arg-OH, in whole or in part, but at least the four carboxyl-terminal amino acids.
- Suitable for the preparation of the peptides according to the invention are conventional methods, for example Merrifield solid-phase peptide synthesis (G. Barany and R. B. Merrifield: “Solid-Phase Peptide Synthesis” in E. Gross and J. Meienhofer: The Peptides, Analysis, Synthesis, Biology, Adademic Press, Inc. 1980) as well as customary synthetic strategies constructing the peptides in the form of soluble peptide segments. The peptide of the structure H-Cys(SH)-Leu-Asp-Glu-Asp-Ser-Asp-Glu-Glu-Arg-Ala-Ile-Glu-Gly-Arg was particularly preferably prepared on the solid phase. The Fmoc group has been used as temporary protective group, and the permanent protective groups used were the O-t-Bu protective group for Asp and Glu, t-Bu for Ser, the Mtr group for Arg and the tert.-butylmercapto group for Cys. The C-terminal amino acids were immobilized via p-alkoxybenzyl ester groups which were bonded to 1% crosslinked polystyrene. The peptides were constructed with repeated elimination of the temporary protective group and condensation of the next, protected amino acid using a condensing agent, preferably a carbodiimide. The peptides were cleaved off the resin by acidolysis with simultaneous deprotection of the side-chain groups. Any sulfhydryl groups to be deprotected are deprotected using tri-n-butylphosphine according to the state of the art. The peptides were purified by ion exchange chromatography, RP-HPLC and gel permeation chromatography. The composition of the peptides was confirmed as correct by amino acid analysis.
- The use of synthetic peptides as antigens in the immunization of animals results in the generation of antibodies specifically directed against the hapten exposed in this peptide. Hence the antibodies generated in this way are each specific for a single antibody-binding site of the complete protein from which the peptide sequence has been derived. Compared with the use of the natural, purified prothrombin fragments F2/F1+2, the use of synthetic peptides has two additional profound advantages; synthetic peptides can be prepared on a large scale and in high purity so that the elaborate isolation and purification of the natural prothrombin fragments is avoided. Whereas the purification of synthetic peptides from byproducts of the synthesis is well established, even technically elaborate enrichment and purification processes for natural prothrombin fragments always result in preparations which contain a proportion of undesired peptides which, although not detectable still has antigenic activity.
- The peptide prepared according to the invention has an amino acid sequence which corresponds completely or in part to the amino acid sequence of prothrombin and is synthesized by one of the conventional processes for peptide synthesis, for example Merrifield synthesis. The selection of the appropriate sequence entails, where possible, selection of the regions which, due to their location on the protein and/or the antigenicity of the exposed epitope, can be predicted to have a highly antigenic effect. The synthetic peptide then has antigenic activity, so that an immune response is triggered by immunization.
- Activated factor X (Xa) cleaves the prothrombin molecule at the recognition sequence Ile-Glu-Gly-Arg. Hitherto This tetrapeptide has been detected only in human and bovine prothrombin. The rarity of this tetrapeptide predisposes it for use as a specific feature of the prothrombin molecule.
- Prothrombin is cleaved by activated factor X next to the arginine of the sequence Ile-Glu-Gly-Arg. Thus, factor Xa generates a new carboxyl terminus which contains in the terminal region the two amino acids GLu and Arg which have a very high antigenicity index. Peptides or polypeptides which contain the recognition sequence of the factor Xa cleavage site at the C terminus are particularly well suited for immunization.
- It has emerged, surprisingly, that antibodies directed against a peptide or polypeptide which contains at its C-terminal end the sequence of the tetrapeptide of the recognition sequence for the factor Xa protease react specifically and exclusively with the prothrombin fragment which has been cleaved off and not with the intact prothrombin molecule.
- The fragment produced by the action of factor Xa on prothrombin and which has the factor Xa recognition sequence at the C terminus has a chain length of 273 amino acids. Suitable for immunization are both the entire polypeptide as well as part-sequences of this peptide which, however, still need to have the factor Xa recognition sequence at the C terminus. A particularly preferred embodiment provides for the use of a tetradecapeptide, for example having the sequence Leu-Asp-Glu-Asp-Ser-Asp-Glu-Glu-Arg-Ala-Ile-Glu-Gly-Arg-OH. The only important point in each case is that the carboxyltenunal sequence of the molecule is exposed and results in the immunization.
- Shorter peptides suffice in cases where it is not intended for the peptide to trigger an immune response but it is intended that the only function of this peptide is to be recognized by existing antibodies. An embodiment appropriate for this is based on an octapeptide of the sequence Glu-Glu-Arg-ALa-lle-Glu-Gly-Arg-OH.
- In view of the intended use of the peptides, it is appropriate to introduce amino acids with reactive side groups into the peptides in such a way that they do not affect the structure of the hapten. For this reason, it is expedient to attach to the N terminus cysteine as a further amino acid, the free SH group of which is suitable for coupling via thioethers to many carriers. An example which is preferably provided is the antigen represented by the abovementioned peptide in the form of the pentadecapeptide Cys(SH)-Leu-Asp-Glu-Asp-Ser-Asp-GLu-Glu-Arg-Ala-Ile-Glu-Gly-Arg.
- The peptide used for the immunization can be prepared both by customary means by chemical synthesis and by purification of a polypeptide made available by genetic manipulation. A conceivable example would be genetic engineering synthesis of the prothrombin fragment F2 or F1+2 in E. coli controlled by a strong promoter, or else the synthesis, by genetic manipulation, of a peptide extending beyond the factor Xa cleavage site or a peptide which is subsequently cleaved in vitro by factor Xa, which is likewise obtained by genetic engineering, which results in accessibility to the desired antigenic carboxyl terminus.
- It is worthwhile for peptides which are intended to be used for immunization, or those intended to be employed as an immunoadsorbent, to be coupled to a carrier molecule. Examples of customary carrier molecules which are widely used are bovine serum albumin, ovalbumin and polysaccharides. In a preferred embodiment, the peptide or polypeptide is bound to keyhole limpet hemocyanin.
- When the synthetic peptides according to the invention are used as immunoadsorbents, it is advisable to couple to materials suitable for preparing solid matrices. A preferred embodiment provides for the coupling of short peptides, for example the abovementioned octapeptide, to Sepharose which has been activated with cyanogen bromide.
- Immunization of suitable animals with carrier-bound peptides results reproducibly in the production of antibodies. A preferred animal species for immunization and obtaining antibodies in this context is the rabbit, because in this case there is a favorable relationship between the blood volume obtainable and the expense of breeding and care.
- The immunoglobulin fraction relevant for specific assays can be enriched by customary immunoadsorption methods from an antiserum of this type generated in an animal using synthetic peptides according to the invention. However, it is preferred in this case likewise to use as material for a matrix of this type, which is employed for immunoadsorption, a peptide which is coupled to a carrier and has the same antigenic determinant as the peptide employed for the immunization. The peptide used for the purification by immunoadsorption can moreover be considerably shorter; the only prerequisite for use in purification of the desired antibody by immunoadsorption is that the antigenic determinant formed by this shorter polypeptide is recognized and efficiently bound by the desired antibody.
- The peptide used for purification of the antibodies by immunoadsorption can be, for example, an octapeptide, preferably the peptide H-Glu-Glu-Arg-Ala-Ile-Glu-GLy-Arg.
- According to the invention, antibodies are induced in the animal system by immunization with synthetic peptides and are purified by immunoadsorption. These antibodies react specifically with the peptides used for the immunization and purification. Depending on the sequence of the peptide used, these antibodies bind either only to the fragments F2 and F1+2 or else, if a peptide sequence which is exposed in the natural prothrombin molecule is chosen, to the intact prothrombin molecule.
- It is possible, by choosing appropriate peptides as immunoadsorbents, to select antibodies which react specifically with the antigenic determinant of prothrombin which corresponds to the sequence of the factor Xa cleavage site of this molecule; in the preferred case where peptides which have the factor Xa-recognition sequence at the C terminus are used both for the immunization and for the purification by immunoadsorption there is enrichment of antibodies against this sequence, but these do not react with intact natural prothrombin, because the factor Xa cleavage site in the natural prothrombin molecule either is not sufficiently exposed or does not have the higher structure required for recognition as an antigen.
- The antibodies obtained according to the invention can be employed for a number of immunoassays with a variety of designs. For this purpose, they are expediently coupled to a solid carrier, but are preferably immobilized by adsorption onto polystyrene tubes. The tubes prepared for the following immunoassays can then be stored, closed airtight, at 4° C.
- The amount of prothrombin fragments F2/F1+2 is determined according to the invention by preincubation of the sample with immobilized antibodies of this type, with the concentration of the fragments F2/F1+2 which are bound by the immobilized antibodies being detected by subsequent incubation with a second antibody. This second antibody must have a property which is measurable, for example the ability to react with or bind a chromogenic substrate.
- It is expedient for this second antibody to be coupled to a marker enzyme, preferably peroxidase. However, it is also possible to choose to provide the second antibody either with a fluorescent molecule, for example fluorescein isothiocyanate or else with a radioactive label.
- The prothrombin fragments F2/F1+2 can also be determined by simultaneous incubation of the sample, preferably of plasma, and labeled antibodies with the immobilized antibodies. Also possible is a competitive determination method entailing competition of labeled and unlabeled prothrombin fragments F2/F1+2 for the binding site on the immobilized antibodies.
- The concentration of prothrombin fragments F2/F1+2 determined in this way provides information on the degree of activation of the prothrombin.
- The examples illustrate the invention. The following abbreviations are used in the examples:
FPA fibrinopeptide A ELISA enzyme immunoassay (enzyme-linked immunosorbent immunosorbent assay) RIA raddio immunoassay KLH keyhole limpet hemocyanin PBS phosphate-buffered saline Tris tris(hydroxymethyl )aminomethane EDTA ethylenedinitrilotetraacetic acid OD absorbance (optical density) Asp L-aspartic acid Ala L-alanine Arg L-arginine Gly glycine Glu L-glutamic acid Ile L-isoleucine Ser L-Serine Cys(SH) L-cysteine Fmoc 9-fluorenylmethytoxycarbonyl O-t-Bu tert.-butyl ester t-Bu tert.-butyl ether Mtr 4-methoxy-2,3,6-trimethylphenylsulfonyl DMF dimethyl formamide RP-HPLC reversed phase high performance Liquid chromatography GMBS gamma-maleimidobutyric acid hydroxysuccinimide ester - Preparation Of an Antigen For the Immunization
- a) Peptide Synthesis For the Pentadecapeptide H-Cys(SH)-Leu-Asp-Glu-Asp-Ser-Asp-Glu-Glu-Arg-Ala-Ile-Glu-Gly-Arg
- The peptide was synthesized using a semiautomatic peptide synthesizer. 1 g of Fmoc-Arg (Mtr)-p-alkoxybenzyl ester-resin was deprotected with 15 ml of 20% piperidine/DMF (v/v) and then washed several times with DMF and isopropanol. 1 mmol of Fmoc-Gly (3-fold excess) and 203 mg of HOBt dissolved in 15 ml of DMF were added. 1.1 ml of a 1 M diisopropylcarbodiimide solution (dichloromethane) were added and then the coupling was carried out for 1.5 hours. Excess reagents were removed by washing with DMF and isopropanol. This coupling scheme was maintained up to the N-terminal amino acid. The last amino acid employed was a Boc-protected amino acid. Every coupling step was checked for completeness by a ninhydrin test. 1.06 g of resin were stirred with 2.5 ml of thioanisole, 2.5 ml of ethanedithiol and 15 ml of trifluoroacetic acid at 35° C. for 4 hours and were filtered off. The acidic solution was poured into ether, and the precipitated peptide was filtered off and chromatographed on a Sephadex(R) G 25 column (3×100 cm, 0.5% acetic acid). The peptide pool was lyophilized. Yield: 230 mg of peptide.
- b) Deprotection Of the Sulfhydryl Group
- 70 mg of the peptide were dissolved in 7 ml of trifluoroethanol and 350 μl of water, and the pH was adjusted to 7.3 with N-methylmorpholine. The reaction vessel was flushed with nitrogen, and 40 μl of n-tributylphosphine were added. The mixture was stirred at room temperature for 1 hour and was diluted with 50 ml of water, and the pH was adjusted to 4.0. The aqueous phase was extracted three times with 10 ml of diethyl ether, concentrated to 10 ml and purified on Sephadex(R) G 25 (3×100 cm; 0.5% acetic acid). Yield: 55 mg of peptide.
- c) Preparation Of Conjugate
- 30 mg of keyhole limpet hemocyanin were dissolved in 0.05 mM sodium phosphate buffer, pH 8.0, and were activated with 3 mg of GMBS for 1 hour. The protein was chromatographed on a Sephadex(R) G 50 column (2×30 cm) (0.1 M sodium phosphate; 0.5 mM EDTA, pH 6.0). The protein pool was concentrated to 6 ml and incubated with 30 mg of the peptide containing sulfhydryl groups for 1 hour. Yield after dialysis and lyophilization: 38 mg of peptide conjugate.
- Immunization Of Rabbits
- 5 rabbits were immunized with 2 mg of antigen per animal each time for a period of 8 weeks; the peptide-KLH conjugate administrations were given subcutaneously and intravenously. The animals were then exsanguinated, and the resulting crude antisera were pooled and stabilized with preservative. Yield: 850 ml of antiserum.
- Preparation Of Immunoadsorbents
- For the purification of the crude antisera by affinity chromatography, about 20 mg of the octapeptide with the sequence H-Glu-Glu-Arg-Ala-Ile-Glu-Gly-Arg-OH (prepared as in Example 1a) were covalently immobilized on a solid phase. The coupling reaction was carried out with Sepharose activated with cyanogen bromide by a described method (Axen, R. et al., Nature, 214, 1302, 1967). The immunoadsorbent was then in each case washed with phosphate-buffered saline (PBS; 0.15 mol/l, pH 7.2) and acetic acid (0.5 mol/l, pH 2.5). Before use, the adsorbent was equilibrated with 3 times the gel volume of PBS. Yield: about 20 ml of peptide-Sepharose.
- The tetradecapeptide prepared as in Example 1 was used in the same way to prepare an immunoadsorbent.
- Isolation Of Specific Antibodies
- 100 ml of crude antiserum were applied to the octapeptide-Sepharose (1.5×15 cm) equilibrated with PBS, and subsequently washed with PBS until the absorbance at 280 nm was 0.01. This was followed by washing steps with saline (1 mol/l, pH 7.0) and water (pH 7.0), with 3 times the gel volume being used in each case. The antibodies were eluted from the immunoadsorbent with 0.1 mol/l acetic acid (pH 2.5), and the antibody solution was adjusted to pH 7.0 with solid sodium phosphate (0.01 mol/l), concentrated (Amicon membrane) and stored at −70° C. Yield: 35 to 40 mg of antibody.
- Assays Of the Antibodies Obtained By Immunoadsorption.
- a) Preparation Of Antibody-Coated Tubes
- The antibodies obtained in Example 4 were diluted with tris buffer solution (0.025 mol/l, pH 7.6) to a concentration of 5 μg/ml and immobilized by adsorption onto polystyrene tubes. 250 μl of antibody solution were incubated in each tube at 20° C. for 20 hours, and then the liquid was removed by aspiration, and the tubes were sealed airtight and stored at 4° C.
- b) Procedure For the Enzyme Immunoassay (ELISA)
- The samples to be assayed (plasma, serum) were diluted 1:1 with incubation buffer (0.01 mol/l tris, 0.01 mol/L EDTA, heparin (2 U/mL), 0.05% Tween, pH 7.6), and 200 μl samples in each tube (see Example 5a) were incubated at 37° C. for 30 min. The incubation solution was then removed, and the tube was washed twice with 500 μl of washing solution each time (0.02 mol/l sodium phosphate, 0.05% Tween, pH 7.6). Then 200 μl of peroxidase-conjugated anti-prothrombin antibodies were added, and the tubes were incubated at 37° C. for 30 min. After removal of the conjugate solution and two washes, 200 μl of substrate/chromogen solution (hydrogen peroxide; o-phenylenediamine) were added, and the tubes were incubated at room temperature. After incubation for ½ an hour, the peroxidase was inactivated with sulfuric acid, and the absorbance of the reaction solution at 492 nm was determined.
- The absorbances at 492 nm as a function of the plasma or serum dilution are shown in the table which follows, comparing with the absorbance of a tube without plasma or serum.
TABLE 1 Dilution OD492/30 min Plasma 1:10 0.13 1:100 0.12 1:1000 0.11 1:10000 0.11 Serum 1:10 3.72 1:100 3.71 1:1000 2,81 1:10000 0.97 Guffer blank 0.045 - c) Procedure For an Enzyme Immunoassay (ELISA) For Determining Fragments F2/F1+2 Formed In Vitro.
- Another experiment was carried out to examine the specificity of the antibodies against the fragments F2/F1+2. Plasma anticoagulated with citrate solution was recalcified with calcium chloride solution (final concentration of calcium chloride: 0.025 mol/l). Aliquots were removed at various times, and the reaction was stopped by addition of EDTA (0.1 mol/l), antithrombin III (3 IU/mL) and heparin (5 IU/ml). The samples were diluted 1:1 with incubation buffer and assayed using the ELISA.
- The table shows the results.
TABLE 2 Time (min) OD492/39 min. 0 0, 18 3 0, 30 6 0, 32 12 0, 58 15 1, 20 18 1, 69 21 1, 88 25 1, 96 Buffer blank 0, 045 - The results show that the fragments F2/F1+2 can be measured quantitatively in this way: the concentration of the fragments F2/F1+2 increases with increasing time during the recalcification reaction.
- The peptides according to the invention, which have an amino acid sequence which corresponds, in whole or in part, to the amino acid sequence of prothrombin and is antigenic thus induce binding-specific antibodies against each of the antigenic determinants present in the peptide. These specific antibodies can then be purified by immunoadsorption on peptides having the same antigenic determinants. The use of synthetic peptides has the considerable advantage that absolutely pure antigens are employed for the immunization, so that no cross-reaction whatever with other proteins or other parts of the prothrombin molecule can occur in the resulting immune serum. Preferably used according to the invention is a peptide which contains the factor Xa cleavage site. Using an antibody against this peptide it is possible to detect only cleaved prothrombin molecules, because this sequence is not accessible to antibody recognition in intact natural prothrombin. Measurement of the quantity of bound antibody provides direct information on the concentration of liberated prothrombin fragments F2/F1+2 and thus on the degree of activation of prothrombin.
-
1 5 1 4 PRT Artificial Sequence Description of Artificial Sequence Synthetic peptide 1 Ile Glu Gly Arg 1 2 50 PRT Artificial Sequence Description of Artificial Sequence Synthetic peptide 2 Gly Asp Glu Glu Gly Val Trp Cys Tyr Val Ala Gly Lys Pro Gly Asp 1 5 10 15 Phe Gly Tyr Cys Asp Leu Asn Tyr Cys Glu Glu Ala Val Gln Glu Glu 20 25 30 Thr Gly Asp Gly Leu Asp Glu Asp Ser Asp Glu Glu Arg Ala Ile Glu 35 40 45 Gly Arg 50 3 15 PRT Artificial Sequence Description of Artificial Sequence Synthetic peptide 3 Cys Leu Asp Glu Asp Ser Asp Glu Glu Arg Ala Ile Glu Gly Arg 1 5 10 15 4 14 PRT Artificial Sequence Description of Artificial Sequence Synthetic peptide 4 Leu Asp Glu Asp Ser Asp Glu Glu Arg Ala Ile Glu Gly Arg 1 5 10 5 8 PRT Artificial Sequence Description of Artificial Sequence Synthetic peptide 5 Glu Glu Arg Ala Ile Glu Gly Arg 1 5
Claims (11)
1. Peptides which have amino acid sequences which partly correspond to the carboxyl-terminal end of the fragments F2/F1+2 resulting from the F Xa cleavage of prothrombin, and which contain the amino acid sequence H-Gly-Asp-Glu-Glu-Gly-Val-Trp-Cys-Tyr-Val-Ala-Gly-Lys-Pro-Gly-Asp-Phe-Gly-Tyr-Cys-Asp-Leu-Asn-Tyr-Cys-Glu-Glu-Ala-Val-Gln-Glu-Glu-Thr-Gly-Asp-Gly-Leu-Asp-Glu-Asp-Ser-Asp-Glu-Glu-Arg-Ala-Ile-Glu-Gly-Arg-OH, in whole or in part, but at least the four carboxyl-terminal amino acids.
2. A peptide as claimed in claim 1 , which has the amino acid sequence H-Leu-Asp-Glu-Asp-Ser-Asp-Glu-Glu-Arg-Ala-ILe-Glu-Gly-Arg-OH, H-Glu-GLu-Arg-Ala-ILe-Glu-Gly-Arg-OH or H-Cys(SH)-Leu-Asp-GLu-Asp-Ser-Asp-Glu-Glu-Arg-Ala-Ile-Glu-Gly-Arg.
3. Peptides as claimed in claim 1 , which are prepared by genetic manipulation or by chemical synthesis.
4. A peptide as claimed in claim 1 , which is bound to an insoluble polymeric carrier or keyhole limpet hemocyanin, albumin or ovalbumin.
5. The use of the peptides as claimed in claim 1 for the immunization of an animal, preferably of a rabbit, and for the purification of specific antibodies against the said peptide by means of immunoadsorption.
6. The use of a polypeptide as claimed in claim 5 , wherein the peptide has the amino acid sequence H-Glu-Glu-Arg-Ala-Ile-Glu-Gly-Arg-OH.
7. Antibodies against peptides as claimed in claim 1 , which have been obtained by immunization of an animal with a peptide as claimed in at least one of claims 1 to 4 and subsequent purification by immunoadsorption as claimed in at least one of claims 5 or 6.
8. Antibodies as claimed in claim 7 , which react specfically with a peptide as claimed in claim 1 and/or with natural prothrombin or parts thereof.
9. Antibodies as claimed in claim 8 , which are specific for binding to the prothrombin fragments F2/F1+2 and are coupled to a carrier.
10. A method for the determination of prothrombin fragment F1+2/F2 using antibodies as claimed in at least one of claims 7 to 9 , which comprises the prothrombin fragments F2/F1+2 being bound to the specific antibodies and being detected by a second antibody, and comprises the quantity of the bound second antibody being measurable.
11. The use of antibodies as claimed in claim 10 , wherein a marker enzyme, preferably peroxidase, is bound to the second antibody.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/356,342 US20040053372A1 (en) | 1987-08-19 | 2003-01-31 | Synthetic peptides, antibodies directed against them, and the use thereof |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP3727610.7 | 1987-08-19 | ||
DE19873727610 DE3727610A1 (en) | 1987-08-19 | 1987-08-19 | SYNTHETIC PEPTIDES, AGAINST THESE ANTIBODIES AND THEIR USE |
US07/234,121 US5071954A (en) | 1987-08-19 | 1988-08-17 | Synthetic prothrombin peptides and antibodies directed against them |
US07/794,495 US6566085B1 (en) | 1987-08-19 | 1991-11-20 | Synthetic peptides, antibodies directed against them, and the use thereof |
US10/356,342 US20040053372A1 (en) | 1987-08-19 | 2003-01-31 | Synthetic peptides, antibodies directed against them, and the use thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/794,495 Continuation US6566085B1 (en) | 1987-08-19 | 1991-11-20 | Synthetic peptides, antibodies directed against them, and the use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040053372A1 true US20040053372A1 (en) | 2004-03-18 |
Family
ID=6334036
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/234,121 Expired - Lifetime US5071954A (en) | 1987-08-19 | 1988-08-17 | Synthetic prothrombin peptides and antibodies directed against them |
US07/794,495 Expired - Lifetime US6566085B1 (en) | 1987-08-19 | 1991-11-20 | Synthetic peptides, antibodies directed against them, and the use thereof |
US08/475,828 Expired - Lifetime US6538113B1 (en) | 1987-08-19 | 1995-06-07 | Methods of obtaining antibody directed against prothrombin fragments F2/F1+2 |
US10/356,342 Abandoned US20040053372A1 (en) | 1987-08-19 | 2003-01-31 | Synthetic peptides, antibodies directed against them, and the use thereof |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/234,121 Expired - Lifetime US5071954A (en) | 1987-08-19 | 1988-08-17 | Synthetic prothrombin peptides and antibodies directed against them |
US07/794,495 Expired - Lifetime US6566085B1 (en) | 1987-08-19 | 1991-11-20 | Synthetic peptides, antibodies directed against them, and the use thereof |
US08/475,828 Expired - Lifetime US6538113B1 (en) | 1987-08-19 | 1995-06-07 | Methods of obtaining antibody directed against prothrombin fragments F2/F1+2 |
Country Status (7)
Country | Link |
---|---|
US (4) | US5071954A (en) |
EP (1) | EP0303983B1 (en) |
JP (1) | JP2735233B2 (en) |
AT (1) | ATE94880T1 (en) |
AU (1) | AU612683B2 (en) |
CA (1) | CA1339027C (en) |
DE (2) | DE3727610A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100081212A1 (en) * | 2008-09-30 | 2010-04-01 | Matthias Ehm | Antibodies for determining the prothrombin fragment f2/f1+2 in a homogeneous immunoassay |
US10131896B2 (en) | 2013-10-29 | 2018-11-20 | Omrix Biopharmaceuticals Ltd. | Compounds and methods for stabilizing thrombin activity |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3727610A1 (en) | 1987-08-19 | 1989-03-02 | Behringwerke Ag | SYNTHETIC PEPTIDES, AGAINST THESE ANTIBODIES AND THEIR USE |
US6541275B1 (en) * | 1988-02-03 | 2003-04-01 | Dade Behring Inc. | Immunoassay for F1.2 prothrombin fragment |
IE903930A1 (en) * | 1989-11-06 | 1991-05-08 | Akzo Nv | Immunoassays for and monoclonal antibodies to prothrombin¹activation peptides and their degradation products |
CA2131389A1 (en) * | 1992-03-02 | 1993-09-16 | John M. Maraganore | Thrombin receptor antagonists |
US5516889A (en) * | 1993-06-21 | 1996-05-14 | University Technologies International, Inc. | Synthetic thrombin receptor peptides |
US6127524A (en) * | 1996-10-18 | 2000-10-03 | Dade Behring Inc. | Binding molecules and computer-based methods of increasing the binding affinity thereof |
US6503724B1 (en) | 1998-05-18 | 2003-01-07 | Link Enterprises Corporation | Fibrinopeptides in saliva as indicator of blood coagulation status |
WO2001063299A1 (en) * | 2000-02-23 | 2001-08-30 | Besst-Test Aps | METHOD FOR CORRELATING BLOOD COAGULATION ACTIVITY WITH MARKERS IN BODY FLUIDS, e.g. URINE |
DE10354403A1 (en) | 2003-11-20 | 2005-06-23 | Dade Behring Marburg Gmbh | Antibodies directed against the prothrombin fragment F 1 + 2, their preparation and use |
EP4239338A1 (en) | 2022-03-03 | 2023-09-06 | Siemens Healthcare Diagnostics Products GmbH | Global test for determining the status of the blood coagulation system |
EP4325224A1 (en) | 2022-08-18 | 2024-02-21 | Siemens Healthcare Diagnostics Products GmbH | Thrombocyte activation test for diagnosing heparin-induced thrombocytopenia |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4287180A (en) * | 1980-01-28 | 1981-09-01 | Baxter Travenol Laboratories, Inc. | Method for treating blood clotting factor inhibitors |
US4289498A (en) * | 1979-01-08 | 1981-09-15 | Ortho Diagnostics, Inc. | One-stage prothrombin assay and compositions useful therein |
US4334018A (en) * | 1977-12-24 | 1982-06-08 | Boehringer Mannheim Gmbh | Process and reagent for the determination of prothrombin |
US4357321A (en) * | 1980-01-28 | 1982-11-02 | Baxter Travenol Laboratories, Inc. | Method and composition for treating clotting factor inhibitors |
US4459288A (en) * | 1981-05-11 | 1984-07-10 | Baxter Travenol Laboratories, Inc. | Therapeutic blood clotting factor compositions and their use |
US4465623A (en) * | 1979-05-04 | 1984-08-14 | Societe Anonyme Dite: Institut Merieux | Prothrombin complex concentrates, preparation and application thereof |
US4663164A (en) * | 1980-01-28 | 1987-05-05 | Baxter Travenol Laboratories, Inc. | Aqueous compositions for treating blood clotting factor inhibitors |
US4668621A (en) * | 1985-04-22 | 1987-05-26 | Wake Forest University | Detecting blood clotting factors with immobilized fibrinogen and labeled fibrinogen |
US5071954A (en) * | 1987-08-19 | 1991-12-10 | Behringwerke Aktiengesellschaft | Synthetic prothrombin peptides and antibodies directed against them |
US6566285B1 (en) * | 1998-04-15 | 2003-05-20 | Pro-Fit International Limited | Interlining material, process of manufacturing and use thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4769320A (en) * | 1982-07-27 | 1988-09-06 | New England Medical Center Hospitals, Inc. | Immunoassay means and methods useful in human native prothrombin and human abnormal prothorombin determinations |
US4722903A (en) | 1983-11-14 | 1988-02-02 | New York Blood Center, Inc. | Monoclonal antibodies specific to in vivo fragments derived from human fibrinogen, human fiberin I or human fibrin II |
IE903930A1 (en) | 1989-11-06 | 1991-05-08 | Akzo Nv | Immunoassays for and monoclonal antibodies to prothrombin¹activation peptides and their degradation products |
-
1987
- 1987-08-19 DE DE19873727610 patent/DE3727610A1/en not_active Withdrawn
-
1988
- 1988-08-12 DE DE88113124T patent/DE3884316D1/en not_active Expired - Lifetime
- 1988-08-12 EP EP88113124A patent/EP0303983B1/en not_active Expired - Lifetime
- 1988-08-12 AT AT88113124T patent/ATE94880T1/en not_active IP Right Cessation
- 1988-08-17 US US07/234,121 patent/US5071954A/en not_active Expired - Lifetime
- 1988-08-18 JP JP63203944A patent/JP2735233B2/en not_active Expired - Lifetime
- 1988-08-18 CA CA000575049A patent/CA1339027C/en not_active Expired - Lifetime
- 1988-08-18 AU AU21058/88A patent/AU612683B2/en not_active Ceased
-
1991
- 1991-11-20 US US07/794,495 patent/US6566085B1/en not_active Expired - Lifetime
-
1995
- 1995-06-07 US US08/475,828 patent/US6538113B1/en not_active Expired - Lifetime
-
2003
- 2003-01-31 US US10/356,342 patent/US20040053372A1/en not_active Abandoned
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4334018A (en) * | 1977-12-24 | 1982-06-08 | Boehringer Mannheim Gmbh | Process and reagent for the determination of prothrombin |
US4289498A (en) * | 1979-01-08 | 1981-09-15 | Ortho Diagnostics, Inc. | One-stage prothrombin assay and compositions useful therein |
US4465623A (en) * | 1979-05-04 | 1984-08-14 | Societe Anonyme Dite: Institut Merieux | Prothrombin complex concentrates, preparation and application thereof |
US4287180A (en) * | 1980-01-28 | 1981-09-01 | Baxter Travenol Laboratories, Inc. | Method for treating blood clotting factor inhibitors |
US4357321A (en) * | 1980-01-28 | 1982-11-02 | Baxter Travenol Laboratories, Inc. | Method and composition for treating clotting factor inhibitors |
US4663164A (en) * | 1980-01-28 | 1987-05-05 | Baxter Travenol Laboratories, Inc. | Aqueous compositions for treating blood clotting factor inhibitors |
US4459288A (en) * | 1981-05-11 | 1984-07-10 | Baxter Travenol Laboratories, Inc. | Therapeutic blood clotting factor compositions and their use |
US4668621A (en) * | 1985-04-22 | 1987-05-26 | Wake Forest University | Detecting blood clotting factors with immobilized fibrinogen and labeled fibrinogen |
US5071954A (en) * | 1987-08-19 | 1991-12-10 | Behringwerke Aktiengesellschaft | Synthetic prothrombin peptides and antibodies directed against them |
US6566085B1 (en) * | 1987-08-19 | 2003-05-20 | Dade Behring Marburg Gmbh | Synthetic peptides, antibodies directed against them, and the use thereof |
US6566285B1 (en) * | 1998-04-15 | 2003-05-20 | Pro-Fit International Limited | Interlining material, process of manufacturing and use thereof |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100081212A1 (en) * | 2008-09-30 | 2010-04-01 | Matthias Ehm | Antibodies for determining the prothrombin fragment f2/f1+2 in a homogeneous immunoassay |
US9096674B2 (en) | 2008-09-30 | 2015-08-04 | Siemens Healthcare Diagnostics Products Gmbh | Antibodies for determining the prothrombin fragment F2/F1+2 in a homogeneous immunoassay |
US10131896B2 (en) | 2013-10-29 | 2018-11-20 | Omrix Biopharmaceuticals Ltd. | Compounds and methods for stabilizing thrombin activity |
AU2014343199B2 (en) * | 2013-10-29 | 2019-01-03 | Omrix Biopharmaceuticals Ltd. | Compounds and methods for stabilizing thrombin activity |
US10435681B2 (en) | 2013-10-29 | 2019-10-08 | Omrix Biopharmaceuticals Ltd. | Compounds and methods for stabilizing thrombin activity |
Also Published As
Publication number | Publication date |
---|---|
US5071954A (en) | 1991-12-10 |
AU2105888A (en) | 1989-02-23 |
DE3884316D1 (en) | 1993-10-28 |
ATE94880T1 (en) | 1993-10-15 |
US6538113B1 (en) | 2003-03-25 |
CA1339027C (en) | 1997-03-25 |
JPS6470498A (en) | 1989-03-15 |
AU612683B2 (en) | 1991-07-18 |
EP0303983A2 (en) | 1989-02-22 |
EP0303983A3 (en) | 1990-08-08 |
EP0303983B1 (en) | 1993-09-22 |
DE3727610A1 (en) | 1989-03-02 |
US6566085B1 (en) | 2003-05-20 |
JP2735233B2 (en) | 1998-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5516639A (en) | Antibodies specific for human prostate glandular kallkrein | |
US6441141B1 (en) | Synthetic peptides, antibodies against them and their use | |
Scheefers-Borchel et al. | Discrimination between fibrin and fibrinogen by a monoclonal antibody against a synthetic peptide. | |
Hurley et al. | Development of radioimmunoassays for free tetra-L-aspartyl-L-lysine trypsinogen activation peptides (TAP) | |
US5071954A (en) | Synthetic prothrombin peptides and antibodies directed against them | |
JPH05184384A (en) | Monoclonal antibody to recognize c end of hbnp | |
US5490981A (en) | Diagnostic and therapeutic compositions and methods for lipoprotein(a) | |
AU595479B2 (en) | Determination of fibrin using fibrin-specific antibodies | |
EP1780219A2 (en) | Protein S polypeptides and uses thereof | |
US5254672A (en) | Synthetic peptides which contain sequences from factor VIIa, and the use thereof | |
JP2634683B2 (en) | Antibodies to fibrin; immunogenic peptides suitable for antibody preparation, methods for determining fibrin, and antibody-based preparations | |
JPH09249699A (en) | Antihuman pivka-ii monoclonal antibody, hybridoma capable of producing the same antibody and measuring reagent and measurement using the same antibody | |
US5099004A (en) | Antibodies against fibrin: immunogen to be used for the preparation of the antibodies, procedure for determining fibrin with the antibodies and pharmaceutical preparation based on the antibodies | |
EP0524737A2 (en) | Protein s. polypeptides and anti-peptide antibodies that inhibit protein s binding TO C4b binding protein, diagnostic systems and therapeutic methods | |
FI86255C (en) | MONOCLONAL ANTIUROKINASE-ANTIKROPP, DEN INNEHAOLLANDE MATRIX OCH BIOCHEMICAL TESTING, I VILKA DEN ANVAENDES. | |
CA2165672C (en) | Antibodies specific for human prostate glandular kallikrein | |
JPH0291097A (en) | Peptide having prourokinase and its production | |
TAKEYAMA et al. | Immuno-affinity purification of specific antibodies against vasoactive intestinal polypeptide (VIP) on VIP (1-10)-linked polydimethylacrylamide resin | |
EP0705841A1 (en) | Peptides havng antigenic activity against hepatitis A virus (HAV) | |
Zhang et al. | Generation of an antibody with a designed specificity difference for protein C and activated protein C | |
EP0764657A1 (en) | Diagnostic and therapeutic compositions and methods for lipoprotein(a) | |
CA2021779A1 (en) | Monoclonal antibody to endothelin-3 or precursor thereof and use thereof | |
JPH10179159A (en) | Monoclonal antibody, its application as immunological adsorbent and production of human plasminogen using the adsorbent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |